Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Invest New Drugs. 2010 Jan 15;29(3):473–480. doi: 10.1007/s10637-009-9381-y

Table 4.

Best response on study. The best antitumor response by RECIST criteria for each cohort. PR partial response, SD stable disease, PD progressive disease, TE/NA toxicity event/not assessed

Best response Cohort A (n=12) Cohort B (n=7) Cohort C (n=11) Cohort D (n=6) Cohort E (n=3) Total (n=39)
PR 2 2 1 0 1 6
SD 2 3 4 4 0 13
PD 4 0 4 0 1 9
TE/NA 4 2 2 2 1 11